Isn't It Hypocritical to Request a P/B Raising Measure While Continuing the Listed Subsidiary IPO?

375 Views04 Feb 2024 07:21
I would like to discuss the issues on the November 26 Nikkei Shimbun article, "MBOs to Top 1 Trillion Yen in 2023, Taisho Pharmaceutical and Benesse Following in Succession."
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 14-minute read)
Discussions
(Paid Plans Only)
chart-bar
x